2013 - Fellow of the American Association for the Advancement of Science (AAAS)
David Ritchie spends much of his time researching Immunology, Internal medicine, Lymphoma, Antigen and Chemotherapy. Immunology and Cancer research are frequently intertwined in his study. His research on Internal medicine frequently connects to adjacent areas such as Oncology.
His Lymphoma study combines topics in areas such as Positron emission tomography and Retrospective cohort study. His Antigen research is multidisciplinary, incorporating perspectives in Cytotoxic T cell and Cell biology. His biological study deals with issues like Aldesleukin, which deal with fields such as Pharmacology.
His scientific interests lie mostly in Internal medicine, Transplantation, Immunology, Oncology and Hematopoietic stem cell transplantation. The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Surgery. His study on Graft-versus-host disease is often connected to Hazard ratio as part of broader study in Transplantation.
His is involved in several facets of Immunology study, as is seen by his studies on Antigen, T cell, Immune system, Leukemia and Myeloid leukemia. His Chemotherapy regimen study in the realm of Oncology interacts with subjects such as In patient. Within one scientific family, David Ritchie focuses on topics pertaining to Radiology under Lymphoma, and may sometimes address concerns connected to Nuclear medicine.
David Ritchie mainly investigates Internal medicine, Transplantation, Stem cell, Oncology and Cancer research. His Internal medicine research incorporates elements of Gastroenterology and Viremia. His research in the fields of Hematopoietic stem cell transplantation and Post transplant overlaps with other disciplines such as Platelet Engraftment.
His research in Stem cell focuses on subjects like Registry study, which are connected to Myeloablative conditioning, Diffuse large B-cell lymphoma and Pathology. David Ritchie has researched Oncology in several fields, including Cancer, Chemotherapy, B-cell lymphoma, Disease and Bone marrow. David Ritchie has included themes like Venetoclax and T cell, CD8, Immune system in his Cancer research study.
David Ritchie mainly focuses on Internal medicine, Transplantation, Cancer research, Oncology and Chimeric antigen receptor. His Gastroenterology research extends to the thematically linked field of Internal medicine. His work on Hematopoietic stem cell transplantation and Graft-versus-host disease as part of general Transplantation research is frequently linked to Exome sequencing, bridging the gap between disciplines.
The various areas that David Ritchie examines in his Cancer research study include Cell and Stem cell. David Ritchie focuses mostly in the field of Cell, narrowing it down to matters related to Ibrutinib and, in some cases, Mantle cell lymphoma and Lymphoma. His research investigates the connection between Oncology and topics such as Inflammation that intersect with problems in Immune system.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
H Quach;D Ritchie;D Ritchie;A K Stewart;P Neeson.
Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.
David S. Ritchie;Paul J. Neeson;Paul J. Neeson;Amit Khot;Stefan Peinert.
Molecular Therapy (2013)
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
Christopher J Chan;Ludovic Martinet;Susan Gilfillan;Fernando Souza-Fonseca-Guimaraes.
Nature Immunology (2014)
CD8+ T Cell-Dependent Elimination of Dendritic Cells In Vivo Limits the Induction of Antitumor Immunity
Ian F. Hermans;David S. Ritchie;Jianping Yang;Joanna M. Roberts.
Journal of Immunology (2000)
Late Ebola virus relapse causing meningoencephalitis: a case report.
Michael Jacobs;Alison Rodger;David J Bell;Sanjay Bhagani.
The Lancet (2016)
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy
Andy K. Hsu;Hang Quach;Hang Quach;Tsin Tai;H. Miles Prince;H. Miles Prince.
Autoimmunity associated with immunotherapy of cancer.
Sally M. Amos;Connie P. M. Duong;Jennifer A. Westwood;David S. Ritchie.
Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity.
A J Davenport;R S Cross;R S Cross;K A Watson;Y Liao.
Proceedings of the National Academy of Sciences of the United States of America (2018)
Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy
Charlotte F. M. Hughes;Charlotte F. M. Hughes;Amit Khot;Christopher McCormack;Christopher McCormack;Stephen Lade.
Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells
Saar Gill;Adrianne E. Vasey;Alysha De Souza;Jeanette Baker.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: